These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2109590)

  • 61. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
    Marschang P; Gürtler L; Tötsch M; Thielens NM; Arlaud GJ; Hittmair A; Katinger H; Dierich MP
    AIDS; 1993 Jul; 7(7):903-10. PubMed ID: 7689323
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.
    Challita-Eid PM; Klimatcheva E; Day BT; Evans T; Dreyer K; Rimel BJ; Rosenblatt JD; Planelles V
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1617-24. PubMed ID: 9870314
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
    Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
    Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.
    Jin Q; Chen H; Wang X; Zhao L; Xu Q; Wang H; Li G; Yang X; Ma H; Wu H; Ji X
    PLoS One; 2015; 10(7):e0131894. PubMed ID: 26154172
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Picard O
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7573-7. PubMed ID: 8356059
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide.
    Jiang A; Fisher H; Pomerantz RJ; Dornburg R
    Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.
    Sheik-Khalil E; Bray MA; Özkaya Şahin G; Scarlatti G; Jansson M; Carpenter AE; Fenyö EM
    BMC Infect Dis; 2014 Aug; 14():472. PubMed ID: 25176034
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A longitudinal magnetization transfer imaging evaluation of brain injury in a macaque model of neuroAIDS.
    Li CX; Herndon JG; Novembre FJ; Zhang X
    AIDS Res Hum Retroviruses; 2015 Mar; 31(3):335-41. PubMed ID: 25376011
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein.
    Lyczak JB; Morrison SL
    Arch Virol; 1994; 139(1-2):189-96. PubMed ID: 7826209
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents.
    Rausch DM; Hwang KM; Padgett M; Voltz AH; Rivas A; Engleman E; Gaston I; McGrath M; Fraser B; Kalyanaraman VS
    Ann N Y Acad Sci; 1990; 616():125-48. PubMed ID: 2078014
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A CD 4: immunoglobulin fusion protein with antiviral effects against HIV.
    Gregersen JP; Mehdi S; Gelderblom H; Zettlmeissl G
    Arch Virol; 1990; 111(1-2):29-43. PubMed ID: 2109590
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments.
    Langner KD; Niedrig M; Fultz P; Anderson D; Reiner G; Repke H; Gelderblom H; Seed B; Hilfenhaus J; Zettlmeissl G
    Arch Virol; 1993; 130(1-2):157-70. PubMed ID: 8503781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
    Traunecker A; Schneider J; Kiefer H; Karjalainen K
    Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.